Please assess the completion status of the following clinical trial:

Trial Title: DLBS1033 for Acute Ischemic Stroke Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent from the patients or patients' legally acceptable representatives (must be obtained before any trial related activities).~* Male or female subjects with age of \>18 years at Screening.~* Patients clinically diagnosed having acute ischemic stroke attack and confirmed by CT scan.~* Patients with cerebral infarction subtypes of PACI or LACI as classified by Bamford criteria.~* Patients with moderate condition based on National Institutes of Health Stroke Scale (NIHSS) score of 5-15.~* Patients present at hospital and receiving first dose of study medication within 72 hours after the onset of the stroke symptoms.~* Able to take oral medication.~Exclusion Criteria:~* For females of childbearing potential: pregnancy and lactation period.~* History of hemorrhagic stroke within the last 3 months.~* Patients with seizure at the onset of stroke or with regular medication for seizure/epilepsy.~* Current or regular use (within the last 1 month) of oral anticoagulants, antiplatelets other than study medication, and herbal medicines.~* Patients who have received tissue plasminogen activator (TPA) within 24 hours to Screening.~* History of serious head injury within the last 3 months.~* History of major surgery within the last 3 months.~* Recent serious cardiovascular conditions, such as myocardial infarction and heart atrial fibrillation as demonstrated by electrocardiography (ECG).~* History of congestive heart failure and aortic dissection.~* Presence of severe renal and hepatic dysfunction, defined as serum creatinine level \> 3x upper limit of normal (ULN) or history of hemodialysis, and any of serum ALT, AST, Gamma-GT level of \> 3x ULN, respectively.~* Presence of acute SIRS.~* Presence of chronic infections.~* Patients with higher risks of bleeding.~* Subjects with uncontrolled hypertension (systolic blood pressure \> 185 mmHg or diastolic blood pressure \> 110 mmHg).~* Subjects with random plasma glucose ≥180 mg/dL and HbA1c ≥ 7.0% at Screening.~* Known or suspected hypersensitivity to the trial product or related products.~* Participation in any other clinical studies within 30 days prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 3 x 1 tablet, given everyday for 28 days of study period
- DLBS1033 (Type: EXPERIMENTAL): DLBS1033 enteric-coated tablet 3 x 490 mg daily, given everyday for 28 days of study period

Based on this trial design, predict the completion outcome and termination type (if applicable).